Notable Upgrades: CEL-SCI Corp. (CVM), Synthetic Biologics (SYN), Mavenir Systems (MVNR), Tracon Pharma (TCON), Zioppharm Oncology (ZIOP)

Analysts at Dawson James initiated coverage on CEL-SCI Corporation (CVM) with an ‘Buy’ rating and a $3.00 price target in a research report issued to clients on Monday. CVM shares recently gained $0.07 to $1.11. In the past 52 weeks, shares of Vienna, Virginia-based drug research company have traded between a low of $0.54 and […] View the full post at: Notable Upgrades: CEL-SCI Corp. (CVM), Synthetic Biologics (SYN), Mavenir Systems (MVNR), Tracon Pharma (TCON), Zioppharm Oncology (ZIOP) Related posts: Insider Selling: Twitter (TWTR) CEO Unloads $5M Worth of Stock